A trial looking at tusamitamab ravtansine for non small cell lung cancer (CARMEN-L03)

Cancer type:

Lung cancer
Non small cell lung cancer




Phase 3

This trial compared tusamitamab ravtansine (SAR408701) to docetaxel to treat non small cell lung cancer. 

It was for people with non small cell cancer that has spread to another part of the body.

More about this trial

Docetaxel is a chemotherapy drug that doctors use to treat non small cell lung cancer. 

Some cancers including lung cancers have a protein called CEACAM5 on their surface. 

Tusamitamab ravtansine is a antibody drug conjugate. It is a combination of a monoclonal antibody Open a glossary item and a chemotherapy drug called ravtansine or DM4. The monoclonal antibody attaches to the CEACAM5 protein on the cancer cell and then releases DM4 into the cancer cell. 

Researchers thought that tusamitamab ravtansine might be as good as or better than docetaxel for non small lung cancer. 

In this trial half the people were to have tusamitamab ravtansine. And the other half were to have docetaxel.

The aims of this trial were to find out:

  • how well tusamitamab ravtansine works compared to docetaxel
  • more about the side effects of tusamitamab ravtansine
  • what happens to it in the body 
  • how it affects quality of life Open a glossary item

Summary of results

This trial closed earlier than planned. This was because none of the hospitals in the UK recruited any patients. 

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Jo Evans

Supported by


If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think